Alkermes earned royalty revenues of $Array2.2 million, up 24.5% on Bydureon. Vivitrol sales surged 28.6% year over year to $38.2 million in the reported quarter on the back of increased adoption by treatment systems, and growth of the state-funded and Medicaid programs.